Selectively targeting myeloid-derived suppressor cells through TRAIL receptor 2 to enhance the efficacy of CAR T cell therapy for treatment of breast cancer

BACKGROUND: Successful targeting of solid tumors such as breast cancer (BC) using chimeric antigen receptor (CAR) T cells has proven challenging, largely attributed to the immunosuppressive tumor microenvironment (TME). Myeloid-derived suppressor cells (MDSCs) inhibit CAR T cell function and persist...

Descripción completa

Detalles Bibliográficos
Autores principales: Nalawade, Saisha A, Shafer, Paul, Bajgain, Pradip, McKenna, Mary K, Ali, Arushana, Kelly, Lauren, Joubert, Jarrett, Gottschalk, Stephen, Watanabe, Norihiro, Leen, Ann, Parihar, Robin, Vera Valdes, Juan Fernando, Hoyos, Valentina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Immune Cell Therapies and Immune Cell Engineering
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8611441/
https://www.ncbi.nlm.nih.gov/pubmed/34815355
http://dx.doi.org/10.1136/jitc-2021-003237

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8611441/
https://www.ncbi.nlm.nih.gov/pubmed/34815355
http://dx.doi.org/10.1136/jitc-2021-003237

Ejemplares similares